RNA respiratory syncytial virus vaccines
US6060308A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Sep 4, 1997 |
| Grant date | May 9, 2000 |
| Priority date | — |
| Expiry date | Sep 4, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/002
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vector comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter is described. Such vector may be used to produce an RNA transcript which may be used to immunize a host, including a human host, to protect the host against disease caused by paramyxovirus, particularly respiratory syncytial virus, by administration to the host.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.